Furthermore, using both immunohistochemical analysis and quantitative proteomics of patient tumors it has been demonstrated that S100A10 levels were unchanged in pancreatitis, but dramatically increased in late stage pancreatic intraepithelial neoplasia lesions and in pancreatic ductal adenocarcinoma lesions. Here, S100A10 is linked to pancreatic ductal adenocarcinoma.